

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
17 and (onecut or OC-2 or OC-3)	1

Database:

[US Patents Full-Text Database](#)
[US Pre-Grant Publication Full-Text Database](#)
[JPO Abstracts Database](#)
[EPO Abstracts Database](#)
[Derwent World Patents Index](#)
[IBM Technical Disclosure Bulletins](#)

17 and (onecut or OC-2 or OC-3)

Refine Search:

[Clear](#)**Search History****Today's Date: 12/7/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	17 and (onecut or OC-2 or OC-3)	1	L10
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	16 and (onecut or OC-2 or OC-3)	0	L9
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	15 and (waardenburg syndrome)	0	L8
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	15 and cancer	936	L7
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	15 and diabetes	258	L6
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	14 and (gene therap?)	1149	L5
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	11 and (transcription factor?)	2959	L4
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	11 and transcription factor?	2959	L3
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	11 and onecut	1	L2
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	vector	198449	L1

WEST**Generate Collection****Search Results - Record(s) 1 through 1 of 1 returned.**

1. Document ID: EP 1105476 A1, WO 200011159 A1, BE 1012123 A3

L2: Entry 1 of 1

File: DWPI

Jun 13, 2001

DERWENT-ACC-NO: 2000-224694

DERWENT-WEEK: 200134

COPYRIGHT 2001 DERWENT INFORMATION LTD

TITLE: New composition useful for treating or preventing diabetes and cancer, contains nucleic acid encoding a ONECUT family protein or corresponding vector or transformed cell

INVENTOR: LEMAIGRE, F; ROUSSEAU, G

PRIORITY-DATA: 1998BE-0000609 (August 17, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 1105476 A1	June 13, 2001	F	000	C12N015/12
WO 200011159 A1	March 2, 2000	F	038	C12N015/12
BE 1012123 A3	May 2, 2000		000	A61K000/00

INT-CL (IPC): A61K 0/00; A61K 38/17; A61K 48/00; C07K 14/47; C12N 5/10; C12N 15/12; C12N 15/86; C12N 15/88

Full	Title	CIT.1	REV.1	CLS.1	REF.1	DRAW.1

Generate Collection

Terms	Documents
11 and onecut	1


Display

50

Documents, starting with Document:

1

Display Format: CIT**Change Format**

WEST**End of Result Set**Generate Collection

L10: Entry 1 of 1

File: USPT

Jan 19, 1999

US-PAT-NO: 5861298

DOCUMENT-IDENTIFIER: US 5861298 A

TITLE: Cathepsin K gene

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Adams; Mark D.	North Potomac	MD		
Blake; Judith A.	Laurel	MD		
Debouck; Christine M.	Wayne	PA		
Drake; Fred H.	Glenmoore	PA		
Fitzgerald; Lisa M.	Germantown	MD		
Fraser; Claire M.	North Potomac	MD		
Gowen; Maxine	Valley Forge	PA		
Hastings; Gregg A.	Thousand Oaks	CA		
Kirkness; Ewen F.	Olney	MD		
Lee; Norman H.	Woodstock	MD		
Rood; Julie	Lansdowne	PA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE	CODE
SmithKline Beecham Corporation	Philadelphia	PA			02	
Human Genome SciencesInc	Rockville	MD			02	

APPL-NO: 8/ 852807

DATE FILED: May 7, 1997

INT-CL: [6] C12N 15/11, C12N 15/57, C12N 15/63, C12P 21/02


US-CL-ISSUED: 435/226; 435/320.1, 435/325, 536/23.2, 536/23.5, 536/24.31

US-CL-CURRENT: 435/226; 435/320.1, 435/325, 536/23.2, 536/23.5, 536/24.31

FIELD-OF-SEARCH: 536/23.2, 536/23.5, 536/24.31, 435/320.1, 435/325, 435/226

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search SelectedSearch ALL

PAT-NO

ISSUE-DATE

PATENTEE-NAME

US-CL

5501969

March 1996

Hastings et al.

435/325

OTHER PUBLICATIONS

Inaoka et al., Biochem. Biophys. Res. Comm. 206:89-96, Jan. 1995.

Bromme et al., Biol. Chem. Hoppe-Seyler 376:379-384, Jun. 1995.

ART-UNIT: 162
PRIMARY-EXAMINER: Grimes; Eric
ATTY-AGENT-FIRM: Han; William T. King; William T.

ABSTRACT:

The invention relates to cathepsin K polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

22 Claims, 31 Drawing figures

FILE 'HOME' ENTERED AT 16:23:36 ON 07 DEC 2001)

FILE 'EMBASE, BIOSIS, CAPLUS, MEDLINE, CANCERLIT' ENTERED AT 16:23:54 ON
07 DEC 2001

L1	260 S (ONECUT OR OC-3)
L2	110 S HUMAN AND L1
L3	228 S OC-3
L4	98 S HUMAN AND L3
L5	37 DUP REM L4 (61 DUPLICATES REMOVED)

d 15 3 ti abs ibib

L5 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2001 ACS
TI ONECUT gene knockout animals and their use as diabetes mod.
AB The invention concerns a non-human animal, in particular a
mammal such as a mouse, comprising a partial or total deletion
coding for a protein of the ONECUT family, in particular the
or OC-3 genes. These transgenic animals provide a
model for diabetes. Thus, hetero- and homozygous Hnf-6 gene
were produced. Insulin prodn. was reduced in heterozygotes and
from homozygotes. Prodn. of .beta.-cell development factors such
neuro-D, neurogenin 3, Pax-6, Pax-4 and Nkx2.2 was reduced in the
homozygotes. Addnl., the development of the islets of Langerhans was
abnormal. These mice exhibited abnormal glucose tolerance tests with
glycosuria and pathol. hyperglycemia and signs of insulin resistance.
Other phenotypic abnormalities were noted.

ACCESSION NUMBER: 2000:145011 CAPLUS
DOCUMENT NUMBER: 132:206570
TITLE: ONECUT gene knockout animals and their use as diabetes
models
INVENTOR(S): Rousseau, Guy; Lemaigre, Frederic
PATENT ASSIGNEE(S): Universite Catholique de Louvain, Belg.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011158	A1	20000302	WO 1999-BE108	19990813
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
BE 1012122	A3	20000502	BE 1998-608	19980817
PRIORITY APPLN. INFO.:			BE 1998-608	19980817
REFERENCE COUNT:	8			
REFERENCE(S):	(1) Ang, S; Cell 1994, V78, P561 CAPLUS (2) Howe, C; WO 9820112 A 1998 CAPLUS (3) Jacquemin, P; Journal of Biological Chemistry 1999, V274(5), P2665 CAPLUS (4) Landry, C; Developmental Biology 1997, V192, P247 CAPLUS (5) Lannoy, V; Journal of Biological Chemistry 1998, V273(22), P13552 CAPLUS			
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

=>

(FILE 'HOME' ENTERED AT 15:05:47 ON 07 DEC 2001)

FILE 'BIOSIS, EMBASE, MEDLINE, CAPLUS, CANCERLIT' ENTERED AT 15:06:56 ON
07 DEC 2001

L1 18371 S PHARMACEUTICAL COMPOSITION
L2 18371 S PHARMACEUTICAL COMPOSITION?
L3 7109 S (HEPATOCTE NUCLEAR FACTOR? OR HNF?)
L4 5722098 S (HEPATOCTE NUCLEAR FACTOR? OR HNF? OR ONECUT OR OC?)
L5 1323 S L1 AND L4
L6 132670 S (HEPATOCTE NUCLEAR FACTOR? OR HNF? OR ONECUT OR OC##)
L7 325 S L1 AND L6
L8 325 DUP REM L7 (0 DUPLICATES REMOVED)
L9 202 S L8 AND PD<=20010220
L10 202 DUP REM L9 (0 DUPLICATES REMOVED)
L11 131 S L10 AND PD<=19980817
L12 15 S L11 AND (GENE THERAP? OR DIABETES OR CANCER OR MELANOMA OR WA

=> d l12 2 ti abs ibib

L12 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2001 ACS
TI Methods for diagnosing and treating **diabetes** and for identifying
therapeutic agents using **hepatocyte nuclear**
factor 4 and its gene
AB A method for detg. if an animal is at risk for **diabetes** is
described. An animal is provided and an aspect of **hepatocyte**
nuclear factor 4 (HNF4) metab. or structure is
evaluated in the animal. An abnormality in the aspect of **HNF4**
metab. or structure is diagnostic of being at risk for **diabetes**.
Also described are methods for evaluating an agent for use in treating
diabetes, methods for treating **diabetes**, and methods for
treating a cell having an abnormality in structure or metab. of
HNF4. Pharmaceutical compns. and vaccine
compns. are also provided. Linkage anal. studies on families with common
form of non-insulin-dependent **diabetes** mellitus (NIDDM) show
that a gene within the MODY 1 region on the long arm of human chromosome
20 (20q) contributes to the development of NIDDM in a significant no. of
diabetic families. This region includes the **HNF4** gene.

ACCESSION NUMBER: 1998:388644 CAPLUS

DOCUMENT NUMBER: 129:65234

TITLE: Methods for diagnosing and treating **diabetes**
and for identifying therapeutic agents using
hepatocyte nuclear factor
4 and its gene

INVENTOR(S): Krolewski, Andrzej S.

PATENT ASSIGNEE(S): Joslin Diabetes Center, Inc., USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9823780	A1	19980604	WO 1997-US21614	19971125 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1996-32043	19961126

=>

(FILE 'HOME' ENTERED AT 15:05:47 ON 07 DEC 2001)

FILE 'BIOGIS, EMBASE, MEDLINE, CAPLUS, CANCERLIT' ENTERED AT 15:06:56 ON
07 DEC 2001

L1 18371 S PHARMACEUTICAL COMPOSITION
L2 18371 S PHARMACEUTICAL COMPOSITION
L3 7109 S (HEPATOCTE NUCLEAR FACTOR? OR HNF?)
L4 5722098 S (HEPATOCTE NUCLEAR FACTOR? OR HNF? OR ONECUT OR OC?)
L5 13223 S L1 AND L4
L6 132670 S (HEPATOCTE NUCLEAR FACTOR? OR HNF? OR ONECUT OR OC##)
L7 225 S L1 AND L6
L8 225 DUP REM L7 (0 DUPLICATES REMOVED)
L9 202 S L8 AND PD<=20010220
L10 202 DUP REM L9 (0 DUPLICATES REMOVED)
L11 131 S L10 AND PD<=19980817
L12 15 S L11 AND (GENE THERAP? OF DIABETES OR CANCER OR MELANOMA OR WA
L13 7122 S (HEPATOCTE NUCLEAR FACTOR? OR HNF? OR ONECUT)
L14 4 S L1 AND L13
L15 4502 S (HEPATOCTE NUCLEAR FACTOR? OR HNF-6 OR ONECUT OR OC-2 OR OC-
L16 3 S L1 AND L15
L17 4 DUP REM L14 (0 DUPLICATES REMOVED)
L18 3 DUP REM L16 (0 DUPLICATES REMOVED)

d 117 1-4 ti abs ibib

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2001 ACS

TI Pharmaceuticals containing **ONECUT** proteins or genes for treating or preventing diabetes, cancer, or Waardenburg syndrome

AB The invention concerns a **pharmaceutical compn.** comprising a nucleotide sequence coding for a protein of the **ONECUT** family, a vector comprising said nucleotide sequence, the protein encoded by said nucleotide sequence, and/or a cell line transformed by said vector and expressing the protein of the **ONECUT** family. The pharmaceutical may be used to treat/prevent diabetes, cancer, or Waardenburg syndrome. Thus, in human skin cells transcription factors OC-2 and **Hnf-6** stimulated expression of the MITF (microphthalmia-assocd. transcription factor) gene. Transcription factor OC-2 was expressed at high levels in these cells, but **Hnf-6** was only weakly expressed. In melanoma cells, however, both transcription factors were expressed to approx. the same level.

ACCESSION NUMBER: 2000:145012 CAPLUS

DOCUMENT NUMBER: 132:203166

TITLE: Pharmaceuticals containing **ONECUT** proteins or genes for treating or preventing diabetes, cancer, or Waardenburg syndrome

INVENTOR(S): Rousseau, Guy; Lemaigre, Frederic

PATENT ASSIGNEE(S): Universite Catholique de Louvain, Belg.

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011159	A1	20000302	WO 1999-BE112	19990817
W: CA, JP, US				
PW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
BE 1012123	A3	20000502	BE 1998-609	19980817
EP 1105476	A1	20010613	EP 1999-939276	19990817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: BE 1998-609 A 19980817
WO 1999-BE112 W 19990817

REFERENCE COUNT: 8

REFERENCE(S): (1) Jacquemin, P; Journal of Biological Chemistry 1999, V274(5), P2665 CAPLUS
(2) Joslin Diabetes Center Inc; WO 9823780 A 1998 CAPLUS
(3) Landry, C; Developmental Biology 1997, V192, P247 CAPLUS
(4) Lannoy, V; Journal of Biological Chemistry 1998, V273(22), P13552 CAPLUS
(5) Menzel, S; WO 9811254 A 1998 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2001 ACS

TI Carboxylic acids and derivatives thereof and **pharmaceutical compositions** containing them

AB In accordance with the present invention, there are provided therapeutically effective compds. comprising an amphipathic carboxylate of the formula R-COOH, or a salt or an ester or amide of such compd., where R designates a satd. or unsatd. alkyl chain of 10-24 carbon atoms, one or

more of which may be replaced by heteroatoms, where one or more of said carbon or heteroatom chain members optionally forms part of a ring, and where said chain is optionally substituted by a hydrocarbyl radical, heterocyclyl radical, lower alkoxy, hydroxyl-substituted lower alkyl, hydroxyl, carboxyl, halogen, Ph or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkynyl)-substituted Ph, C3-C7 cycloalkyl or (hydroxy-, lower alkyl-, lower alkoxy-, lower alkenyl- or lower alkynyl)-substituted C3-C7 cycloalkyl wherein said amphipathic carboxylate is capable of being endogenously converted to its resp. CoA thioester. Many possible therapeutic activities of these amphipathic carboxylates are claimed.

ACCESSION NUMBER: 1999:34841 CAPLUS
DOCUMENT NUMBER: 130:105306
TITLE: Carboxylic acids and derivatives thereof and
pharmaceutical compositions
containing them
INVENTOR(S): Bar-Tana, Jacob
PATENT ASSIGNEE(S): Yissum Research Development Company of the Hebrew
University of Jerusalem, Israel
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9900116	A2	19990107	WO 1998-IB968	19980623
WO 9900116	A3	19990812		
W: AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KF, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, PU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9877839	A1	19990119	AU 1998-77839	19980623
EP 1001755	A2	20000524	EP 1998-925875	19980623
P: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6303653	B1	20011016	US 1998-104880	19980625
PRIORITY APPLN. INFO.:				
			IL 1997-121165	A 19970626
			WO 1998-IB968	W 19980623

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS
TI Methods for diagnosing and treating diabetes and for identifying therapeutic agents using **hepatocyte nuclear factor 4** and its gene
AB A method for detg. if an animal is at risk for diabetes is described. An animal is provided and an aspect of **hepatocyte nuclear factor 4 (HNF4)** metab. or structure is evaluated in the animal. An abnormality in the aspect of **HNF4** metab. or structure is diagnostic of being at risk for diabetes. Also described are methods for evaluating an agent for use in treating diabetes, methods for treating diabetes, and methods for treating a cell having an abnormality in structure or metab. of **HNF4**. **Pharmaceutical compns.** and vaccine compns. are also provided. Linkage anal. studies on families with common form of non-insulin-dependent diabetes mellitus (NIDDM) show that a gene within the MODY 1 region on the long arm of human chromosome 20 (20q) contributes to the development of NIDDM in a

significant no. of diabetic families. This region includes the

HNF4 gene.

ACCESSION NUMBER: 1998:388644 CAPLUS
DOCUMENT NUMBER: 129:65234
TITLE: Methods for diagnosing and treating diabetes and for
identifying therapeutic agents using
hepatocyte nuclear factor
4 and its gene
INVENTOR(S): Krolewski, Andrzej S.
PATENT ASSIGNEE(S): Joslin Diabetes Center, Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9823780	A1	19980604	WO 1997-US21614	19971125
W: CA, JP				
PW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1996-32043	19961126

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS
TI Interleukin-6 inhibition by nucleotide sequence comprising one or more
APRE elements and another transcription factor-binding site
AB The invention relates to a nucleotide sequence, which is able to inhibit
the IL-6 activity, its use in therapy, and **pharmaceutical**
compos. contg. it. In particular, it relates to a nucleotide
sequence which comprises: i) at least one nucleotide sequence that is an
APRE element of the general formula ZXMYKGKAA, wherein; Z represent T or G
or can also be absent, X represents T or can also be absent, M represents
C or A, Y represents C or T and K represents C or T and K represents T or
G, in conjunction with ii) at least one nucleotide sequence constituting a
transcription factor-binding site other than the APRE element, such as
those present in promoter regions.

ACCESSION NUMBER: 1997:18395 CAPLUS
DOCUMENT NUMBER: 126:43612
TITLE: Interleukin-6 inhibition by nucleotide sequence
comprising one or more APRE elements and another
transcription factor-binding site
INVENTOR(S): Serlupi-Crescenzi, Ottaviano; Pezzotti, Annarita
PATENT ASSIGNEE(S): Applied Research Systems, Neth.; Serlupi-Crescenzi,
Ottaviano; Pezzotti, Annarita
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9635782	A1	19961114	WO 1995-EP1778	19950511
W: AU, BY, CA, CN, JP, KR, KZ, MX, RU, UA, US				
FW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2220433	AA	19961114	CA 1995-2220433	19950511
AU 9525267	A1	19961129	AU 1995-25267	19950511
AU 715125	B2	20000120		
EP 834588	A1	19980225	EP 1995-919438	19950511
F: AT, BE, CH, DE, DK, ES, FF, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

CN 1183801	A	19980603	CN 1995-197849	19950511
JP 11504816	T2	19990511	JP 1995-533683	19950511
ZA 9603593	A	19961125	ZA 1996-3593	19960507
US 6004813	A	19991221	US 1997-945726	19971110
PRIORITY APPLN. INFO.:			WO 1995-EP1778	19950511

=>